Sugi Predict

Sugi Predict / Compounds / SCHEMBL22119129

SCHEMBL22119129

SCHEMBL22119129

O=c1[nH]c(Cl)nc2c(F)nn(CCOCCO)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 3/20 0.35
▸ PDE2A O00408 8/20 0.33
▸ USP2 O75604 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ EDNRA P25101 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ HBB P68871 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ PDE6D O43924 1/20 0.32
▸ PDE5A O76074 1/20 0.32
▸ PDE6A P16499 1/20 0.32
▸ PDE6G P18545 1/20 0.32
▸ PDE4A P27815 1/20 0.32
▸ PDE6B P35913 1/20 0.32
▸ PDE6C P51160 1/20 0.32
▸ PDE4B Q07343 1/20 0.32
▸ PDE4C Q08493 1/20 0.32
▸ PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22245117 0.77 — —
SCHEMBL29540271 0.77 — —
SCHEMBL22245116 0.77 RXRA (0.33) PDE2APDE6DPDE5APDE6APDE6G
SCHEMBL22118900 0.76 PNP (0.40) PNP
SCHEMBL22245184 0.75 PDE2A (0.33) PDE2APDE6DPDE5APDE6APDE6G
SCHEMBL22245187 0.75 — —
SCHEMBL22119037 0.74 EGLN1 (0.35) PNPUSP2TSHREDNRAHTR2A
SCHEMBL22119101 0.74 PIM1 (0.43) —
SCHEMBL22245146 0.74 PDE2A (0.34) PNPPDE2APDE6DPDE5APDE6A
SCHEMBL29540356 0.74 PIM1 (0.43) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof Acurx Pharmaceuticals, Inc. (US) 2026-01-27 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 — — US disclosed
US-20220112195-A1 DNA Polymerase IIIC Inhibitors and Use Thereof ACURX PHARMACEUTICALS LLC (US) 2022-04-14 — — US disclosed
EP-3897645-A1 DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF Acurx Pharmaceuticals, LLC (US) 2021-10-27 — — EP disclosed
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2021-05-11 — — US disclosed
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2021-05-11 — — US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 — — US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 — — US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 — — US disclosed
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-07-28 — — US disclosed
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-07-28 — — US disclosed
WO-2020132174-A1 DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF ACURX PHARMACEUTICALS, LLC (US) 2020-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112195-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PNP 147/4885PDE2A 1443/4885USP2 3506/4885
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof POLR1A, POLR2H, POLN PNP 257/4885PDE2A 3722/4885USP2 4351/4885
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PNP 165/4885PDE2A 1365/4885USP2 3471/4885
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PNP 147/4885PDE2A 1443/4885USP2 3506/4885
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PNP 165/4885PDE2A 1365/4885USP2 3471/4885
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB PNP 165/4885PDE2A 1365/4885USP2 3471/4885
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB PNP 147/4885PDE2A 1443/4885USP2 3506/4885
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB PNP 165/4885PDE2A 1365/4885USP2 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.